Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

August 8, 2023

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 68 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and thank you for holding. You are joining Bayer's Investor and Analyst Conference Call covering the Second Quarter 2023 Results, and we're glad to have you with us. During today's recorded presentation, everyone will be in listen-only mode. After the presentation, there will be a question and answer session. Should anyone have trouble hearing the conference, just press the star key and then 0 on your telephone and an operator will assist you. At this point, I'll hand the conference over to Oliver Maier, Head of Investor Relations at Bayer AG. Oliver, please go ahead.

Oliver Maier

executive
#2

Thank you, Natalie. Good morning, and good afternoon to all of you. I want to welcome everyone to Bayer's call covering the Second Quarter and First Half 2023 results. Joining us on this call for the first time is Bill Anderson, who became our new CEO on June first. Bill, it's great to have you with us. What do we have planned for today's call? Bill is going to kick off today's session by sharing his first impressions and insights since taking over. Wolfgang Nickl, our CFO, will provide commentary on the Group's results and guidance. Rodrigo, Stefan, and Heiko will then wrap up by offering some significant color on divisional performance and the respective outlook. Following that, we'll open things up for the Q&A session. As you may have noticed, we have a different setup for this call, including video, and in the past it has been somewhat difficult to properly understand all of the questions. So I'd like to ask everyone to use a landline so we get good audio quality. Headsets or cell phones should not be used when asking questions. As always, I want to begin by drawing your attention to the Safe Harbor Statement that is included, to the cautionary language contained in our Safe Harbor Statement, as well as in all of the material we distributed this morning.

Oliver Maier

executive
#3

That's everything from my side, and now I'll pass things over to you, Bill.

Bill Anderson

executive
#4

Thank you, Oliver, and best of luck to everyone. If you happen to be in the market for a landline, I just caught sight of one and found myself wondering, "Does anybody actually still own a landline?" That's good. That's good. In any case, it's great — really great — to have this opportunity to engage with all of you, and I'm genuinely excited to be here. I'd like to welcome you, and thank you for dialing in to our conference call. This is the first time I've had the chance to address you in a forum like this, and it truly is a pleasure. I'll begin with a few short comments on how our business performed in 2023, and after that I want to offer some reflections from my initial thinking since joining the company. Last, I'd like to lay out what you should expect from me, from the management team, and from Team Bayer over the coming months and beyond. Let me begin with Q2 and our outlook for 2023. As you're aware, at the end of July we had to reduce our guidance for 2023. The main driver was declines tied to glyphosate in our Crop Science business, and obviously, that is not an easy message to bring. Trust means honoring our commitments every single day. Beyond that, there isn't a great deal more to add.

Bill Anderson

executive
#5

We simply need to improve, and in doing so, earn back the confidence you place in us. I see substantial opportunity there. I have no wish to rehash what's behind us. Considerable untapped capability exists across our workforce, our results, and our project streams, and I am certain we can set it free. That leads me to my initial impressions of Bayer. Having come aboard slightly over 4 months ago and begun my role as CEO in June, I've been able to journey around the globe and meet a wide range of Bayer colleagues, partners, customers, and shareholders. Even though every one of these stakeholders views the company from a distinct angle, their input, I can assure you, carries shared threads. People recognize Bayer's promise and its potential. Our mission matters and connects with everyone, and our businesses sit in growing sectors that are important both to people and to the planet. As you know, I firmly believe we can achieve far stronger results by altering how we work. In June, our market-leading Crop Science business set out a vision for regenerative agriculture that benefits on-farm productivity, benefits farmer incomes, and benefits the Earth.

Bill Anderson

executive
#6

The quicker we can turn this into revenue growth, the better it is for everyone. It's excellent to see the first registrations arriving for our Preceon Smart Corn System, a climate-resilient form of one of agriculture's most vital crops and one of Bayer's most important too. Our pharma business keeps producing outstanding momentum on its new launches. We're ahead of schedule on recruitment for our Phase III study program with asundexian, and the FDA has granted us Fast Track designation for both of the indications we're currently pursuing. I've been through patent expirations before, and you, you don't save your way through one. There are moments when the focus should be on margin optimization, and we're being extremely careful with every euro. At this point, it's crucial for us to maximize the launches. Consumer Health keeps generating growth through innovation, through pricing, and by expanding our iconic brands into new markets. Looking ahead, the team is totally focused on beating the market through superior execution, as well as self-care products that are underpinned by strong science. There are opportunities across the company. Our people are ready to go after them, but it's clear that we haven't realized our full potential. I've heard it from everyone I've spoken to, and we have to act on it.

Bill Anderson

executive
#7

The litigation overhang, the corporate bureaucracy, debt levels—all of these things weigh on our ability to focus on the mission, and we need to be honest with ourselves. You know, if those things are distracting you, can you then truly claim "Health for All, Hunger for None" as our mission?... You know, that's where the question about the company's strategy and the structure comes in. This is the question the management team and I are dedicating most of our time to. I'd like to outline how we're approaching it. Put simply, nothing is off the table. In my first months with the company, I've asked difficult questions, and I've had a lot of difficult questions asked of me. I'm grateful for those experiences. We're creating an environment where the most difficult questions are the ones that we ask of ourselves, and we're going after the answers with rigor, with objectivity, and with speed that our stakeholders deserve. We have an open mind, and we're leaving no stone unturned, and that's the attitude we're taking to our strategy and our structure. I'm working with the management team on that, but I'm also in very close contact with the supervisory board and the employee representatives.

Bill Anderson

executive
#8

Three straightforward priorities that the management team and I have set for Bayer underpin everything we're doing. I'd like to walk you through them, since delivering on these consistently is what company leadership is responsible for. Number one, a fulfilled and productive workforce; number two, world-leading innovation; and number three, superior financial performance. Plainly, nothing less will satisfy any of us. These priorities will be the yardstick we're measured against, and every strategic decision we make will be guided by them. That, I believe, is the focus Bayer requires at this moment. It's the focus our people deserve, our customers deserve, and you deserve. That focus, paired with our review of strategic options, makes this an exciting place to be. My team and I look forward to updating you over the coming months on our considerations, ahead of communicating detailed plans and financial targets in early 2024. With that, I'll hand it over to Wolfgang for a closer look at the current figures.

Wolfgang Nickl

executive
#9

Okay, thank you, Bill, and greetings to everyone. From where I sit as well, you've all had a chance to look at our Q2 numbers and the updated guidance we've given for the entire year. What I'd like to do on this call is spend time on some additional context. On a currency- and portfolio-adjusted basis, group sales were down 8%, coming in at EUR 11 billion. Within that, the decline in sales of glyphosate-based herbicides made up EUR 1.2 billion of the total and was what drove the 18.5% decrease in our Crop Science business during the quarter. Pharma's top line came in flat, while Consumer Health posted growth of 5%. Currency headwinds of roughly EUR 550 million weighed on our top line in Q2, in contrast to a substantial tailwind a year earlier. EBITDA before special items fell 25%, to EUR 2.5 billion, once again mostly attributable to lower volumes and prices for glyphosate-based herbicides, along with persistently elevated cost inflation and our continued spending on pharma innovation. The currency impact on earnings came to approximately EUR -120 million. Ongoing savings and cost contingencies partly offset all of this. In addition, as a natural outcome of a compensation plan tied to operational performance, we released roughly EUR 480 million of provisions for short-term incentives across the group, which benefited earnings in Q2.

Wolfgang Nickl

executive
#10

All told, EBITDA margin before special items for Q2 landed at 22.9%. Our core financial result matched the prior year, and our core tax rate for the quarter was 23.7% — sorry, for the quarter. Core earnings per share came to EUR 1.22, roughly EUR 0.70 under the prior year, largely because of the effects I mentioned a moment ago. The biggest gap between core earnings per share and reported earnings per share of EUR -1.92 is a non-cash net impairment of about EUR 2.3 billion that we booked in Q2 within our Crop Science Division. Now let's turn to how our free cash flow developed. During Q2 we posted negative free cash flow of EUR 473 million, versus a positive EUR 1.1 billion a year earlier. Across the first half, free cash flow reached EUR -4.6 billion, against roughly zero last year. Most of that decline stems from weaker operating cash flows in the Crop Science Division, caused by the business downturn, along with higher trade-related working capital. Settlement payouts ran about EUR 890 million higher year to date, reflecting the PCB-related payments we made early in the year.

Wolfgang Nickl

executive
#11

Because of the negative free cash flow and the dividend payout for last year that occurred during Q2, net financial debt rose to EUR 39.6 billion by the close of the second quarter. Let me spend just one more minute on free cash flow, since many of you are likely wondering why we cut our full year guidance from roughly EUR 3 billion down to zero. Crop Science accounts for the main delta. Rodrigo will cover this in greater detail, but our expectations for growth and profitability across the year have come down, largely because of glyphosate. We also anticipate a slower inventory reduction than we previously forecast, given long cycle terms and contractual obligations. On top of that, we expect lower operating cash flow in our pharma division, driven by lower cross profit, higher R&D investments, and accelerated launch inventories. As you can imagine, working capital management sits at the top of our agenda across the whole organization, and we remain laser-focused on meeting our cost-saving targets. Let me also say a brief word about dividends. As all of you know, we have a policy that pays out 30%-40% of the core EPS for a year and the year after.

Wolfgang Nickl

executive
#12

I don't see the free cash flow movement this year as any kind of trend whatsoever, so it shouldn't have any bearing on our dividend policy. For the full year, our current expectation is core EPS of between EUR 6.20 and EUR 6.40. Now let me draw out a few additional specifics regarding the group outlook we already gave you at the end of July. As you're aware, our guidance is always on a constant currency basis. Our newest estimate, using quarter and foreign exchange rates, comes to a EUR 1.7 billion headwind on our top line. That figure matches what we guided before, in effect computed using updated exchange rates on lower sales. Keep in mind that the FX impact on the bottom line isn't anticipated to be material. Given the reduced free cash flow guidance we went through, net financial debt is now expected to land at roughly EUR 36 billion at the close of 2023. Lastly, purely for your models, we now anticipate a reconciliation result of around EUR -500 million, largely reflecting lower incentive assumptions. Every other group KPI remains the same, as the backup of our presentation shows. With that, I'll pass things to you, Rodrigo, to cover Crop Science developments and the divisional outlook.

Rodrigo Santos

executive
#13

Thanks, Wolfgang, and thank you to everyone who's with us today. Now turning to Crop Science, it genuinely comes down to two distinct businesses: glyphosate, and what we call our core — comprising our innovation-driven seed, trade, and digital operations, the new business, plus the remaining crop protection segments. That core is where our investment goes, it's what underpins our growth, and it's essential to achieving the regenerative agriculture vision we laid out for you not long ago in New York, which Bill also referenced. In this presentation, I'll walk you through how the core performed across the first six months, what we expect for the full year, and a closer look at one key segment. Beginning with our first-half results and carrying forward from the Q2 numbers — you'll find this in our appendix — total Crop Science sales were down 9% on a currency- and portfolio-adjusted basis. That net effect came from roughly EUR 560 million, or 5% growth, in the core business, together with a EUR 1.8 billion, or 61%, drop in sales of our glyphosate-based herbicide. Core growth was powered by 10% pricing gains, helped along by new product launches, which more than offset the volume decline.

Rodrigo Santos

executive
#14

That mostly came down to a couple of things: weather-driven decreases in fungicides across EMEA and LatAm, plus lower planted acres and licensing revenue for soybean and cotton in the U.S. On glyphosate in particular, the over 60% drop in sales year to date was driven by volume — volume contributed more than price did. Those volume losses were concentrated mainly in the U.S., where all our retail partners were broadly working down inventory, and where reduced weed pressure stemmed from drought conditions across a significant portion of the corn and soybean growing regions. Because of that falloff in glyphosate sales, our overall Crop Science EBITDA was down year to date, and the margin before special items dropped to roughly 30%, matching the level we saw in 2021. That's against the approximately 36% margin delivered in 2022, which had been lifted by outperformance in glyphosate pricing. Solid pricing in the core and cost savings tempered continued incremental inflation. Now to the outlook, where we expect Crop Science sales for the year to be down 5% on a currency- and portfolio-adjusted basis, versus 1.5% before. That nets out an expected market-leading growth rate of 5%-7% in the core business, driven mostly by pricing, against a 45%-50% decline in sales of our glyphosate-based herbicides.

Rodrigo Santos

executive
#15

What this does is bring our glyphosate sales for the full year back in line with where they stood in 2020, which you can see on slide 24 in the appendix, and it bakes in a robust volume rebound during the second half along with weighted average pricing that's about even with Q2 levels. For EBITDA margin before special items, we now expect 21% at constant currencies. Turning to a closer look at the 2023 outlook for the core business, you'll notice we anticipate robust growth across every region. Looking at segments, corn leads the way as our biggest contributor this year, posting 14% sales growth year to date, helped along by new hybrid launches and the expansion of our trade platforms too. Innovation is driving performance in every region, and in the second half we're continuing with a double-digit price increase in LatAm. For soybeans, we expect things to moderate to flat to up slightly for the year, as growers keep upgrading to Intacta 2 Xtend in Brazil during the second half. That comes after first-half declines driven by lower licensing revenues and acres planted in the U.S. As for cotton, we still expect it to be down, though also moderating as the year progresses.

Rodrigo Santos

executive
#16

The year-to-date decrease is mainly attributable to fewer planted acres in the U.S., in a market where we presently hold about 70% trade share in cotton. Our selective herbicide portfolio keeps posting mid-single-digit sales growth for the year, and insecticides and fungicides, though flat in the first half despite pricing gains of 10% or more, should speed up later in the year. That pickup is anticipated in LATAM, where these segments are expected to bounce back nicely from the double-digit percentage sales decline in Q4 of 2022, which stemmed largely from the adverse weather conditions we experienced. Even with the challenges we faced this year, we stay focused on our strategic priorities and the milestone required to deliver our pipeline. As an example, I would point to the continued upgrade of our most significant segment, our industry-leading corn seed and trade business. Growers throughout the Americas keep asking for more of our third-generation corn rootworm control trait with RNAi technology, which builds on an important insect control offering in our portfolio. What's even more exciting are the ongoing farm trials worldwide for the Preceon Smart Corn System, featuring our short stature corn. This product could transform how farmers grow corn, and for the better.

Rodrigo Santos

executive
#17

Since high winds cause less yield loss, plus greater use of optimizer fertilizer and crop protection, improved field access, and a season-long opportunity for higher planting densities, we see a possible fit across 220 million acres worldwide and peak sales potential above EUR 1.5 billion. In fact, on this slide you can see one of the system's benefits in action, where a ground rig sprayed or tasseled short corn — short stature corn — in an Iowa plot during these past months. In conventional high corn, that application would probably need to be flown on. The progress is exciting, and we look forward to sharing the results this fall. These new corn traits could not succeed, however, without our strong foundation of leading corn seed genetics, which we refresh every year. This year alone, we launched over 250 new hybrids from our precision breeding program, and we would expect to keep doing so at roughly that pace going forward. We remain committed to driving midterm success with technologies such as these. They are critical to delivering our goal of doubling our accessible market and bringing the benefits of regenerative ag to growers around the globe.

Rodrigo Santos

executive
#18

Having said that, I'll hand things over to Stefan.

Stefan Oelrich

executive
#19

Thanks, Rodrigo. Hello, everyone, from my end. As we noted on the previous conference call in May, the second quarter results for our pharmaceutical division reflected a sequential gain over the sluggish beginning in the first three months of the year, on both the top line and the bottom line. While we kept managing our costs and the LOE of Xarelto, we also made solid headway on key elements of our late-stage pipeline and our commercial strategy. Q2 2023 sales were on par with the prior year's second quarter on a currency and portfolio-adjusted basis, while adverse foreign exchange rate movements produced a reported decline of 5% to EUR 4.6 billion. Our two launch assets keep showing really powerful momentum, with Nubeqa almost doubling and Kerendia more than tripling once again. Beyond that, EYLEA delivered very strong and steady volume growth, especially in Canada and in Asia, which more than offset some of the negative pricing pressures we face in other regions, producing total sales growth of 6%. Our radiology business once again turned in a very good performance, with sales rising 7% year on year, fueled by both higher volumes and prices. Xarelto sales dipped slightly, by 3% in the second quarter, mainly because of price pressures across most of our territories, while lower volumes in China were, to a large extent, this time offset by higher shipments in Europe.

Stefan Oelrich

executive
#20

China was still up against a fair amount of headwinds elsewhere in our portfolio too, although at a much lower level than in that very first month, January, of the year. Adalat kept feeling the effect of reduced prices and volumes tied to the country's volume-based procurement program. Beyond that, aspirin sales were hit by inventory destocking. Turning to the bottom line, Q2 EBITDA before special items fell 7% to EUR 1.4 billion, a margin of 30.3%. The main reason for that decrease was larger R&D spending on early-stage clinical development, especially in our cell and gene as well as our chemoproteomics platform, while recruitment in asundexian's Phase III program, OCEANIC, carried on at an accelerated pace. On top of that, the second quarter of last year had benefited from non-recurring profits on the sale of non-core businesses. Now that the first six months are behind us, we clearly have better visibility across the full 12 months of this year, and we expect our Pharmaceuticals division to post full year sales on par with the prior year, slightly below the 1% increase we previously communicated. The main factor here is a weaker than expected post-pandemic recovery in China, where we continue to face volume-based procurement headwinds on Adalat.

Stefan Oelrich

executive
#21

When it comes to Xarelto, sales keep falling at a mid-single-digit rate, driven by pricing pressure and patent expirations in certain markets. On a brighter note, Nubeqa and Kerendia should deliver strong growth and together surpass EUR 1 billion in sales during this year. Regarding EYLEA, sustained solid volume gains have prompted us to nudge our 2023 outlook for the franchise upward — from a prior assumption of roughly flat sales to growth in the low single digits. We had earlier guided to an EBITDA margin before special items above 29% for 2023 at constant currencies; we now expect roughly 28%, reflecting the revised top-line guidance, unfavorable product mix effects, and higher R&D spending, much of it tied to the strong ongoing patient recruitment in Asundexian's Phase III program. I'd also like to use today's opportunity to go deeper on Nubeqa and Kerendia, which already crossed the EUR 500 million combined sales mark in the first half of this year. Those two medicines were the main drivers behind continued growth in our U.S. pharmaceutical business, where sales rose 8% during the first six months of 2023.

Stefan Oelrich

executive
#22

There's still plenty ahead. Now turning to Nubeqa: in under four years since it launched, it has genuinely become Bayer's third-largest single medicine by sales, even though its rollout began right as the COVID-19 outbreak hit. Regionally, the U.S. remains and will stay the largest single market, and there Nubeqa keeps gaining share in both of its indications. Thanks to its distinctive clinical profile, it is now the most prescribed second-generation androgen receptor agonist in the country for non-metastatic castration-resistant prostate cancer. In the metastatic hormone-sensitive setting it already sits at number two, after our ARASENS study results came out a little over a year ago. We're also eager to see data from the Phase III ARNOTE study next year, which, if positive, should help widen this medicine's label further in metastatic prostate cancer. With further approvals starting to come through outside the U.S., Nubeqa's global market position is expanding as well, and I'm especially pleased to tell you that China, one of our focus countries, became the top growth driver outside the U.S. in this year's second quarter. Now on to Kerendia, whose launch performance is just as exciting.

Stefan Oelrich

executive
#23

Actually, it has demonstrated among the most powerful growth trajectories ever witnessed in cardiovascular medicine. And that's even with the access hurdles our sales teams had to contend with during the COVID-19 pandemic, by the time we began launching in the U.S. in the second half of 2021. Since the launch for treating chronic kidney disease with Type II diabetes, we're observing continued market, marketing — sorry, market uptake in the U.S., with broad utility and relevance across general practitioners and specialists, both of which are supported by ongoing inclusions into treatment guidelines and recommendations. Outside the U.S., once again it is China that has begun to lead growth, following the NRDL listing in March and a broadening of the label in May that now also covers early stages of CKD. Because of Kerendia's non-steroidal molecular structure, it possesses a unique clinical profile that clearly sets it apart from other mineralocorticoid receptor antagonists, as shown by its unparalleled high potency and selectivity, along with its equal balance between kidney and heart tissue. As we seek to fully leverage Kerendia's medical profile and commercial potential, our ongoing phase III development program encompasses studies to potentially expand its use into treating heart failure and additional types of CKD.

Stefan Oelrich

executive
#24

That brings me to the end, so I'll pass things along to Heiko. Heiko, it's possible your line is muted.

Heiko Petersen

executive
#25

Can you hear me? Okay. Thanks, Stefan. It's good to connect with you today. I'm glad to now take you through how we performed in Consumer Health — an appealing sector with a meaningful purpose. In a market that's competitive, we again delivered growth on both the top and bottom lines at the same time, and we're tracking well toward the 2023 guidance we provided. In CPA terms, growth was 5% in the second quarter, and that sits on top of a healthy 7% increase in Q2 of last year. The growth was broad-based. We saw contributions from every region, plus fairly broad-based growth across our categories as well. Pain and cardio and cough and cold and dermatology even posted double-digit growth, mostly driven by a successful expansion in dermatology of our Bepanthen innovation Derma, which we took into more countries. Also, our pain brands delivered exceptional growth in Latin America and in Asia Pacific. Generally, cough and cold rates stayed relatively high in Q2 as well — lower than Q1, but still, even so, still pretty high. Lastly, our nutritionals category, which matters a great deal to us, grew low single-digit, yet held a high absolute level post-COVID. This growth came despite some supply constraints, which hit our digestive health category in particular.

Heiko Petersen

executive
#26

You're able to see that with the modest volume growth we achieved, the figure for the quarter landed at -4%. Conversely, we managed to secure 10% in pricing, and that speaks to how strong our brands are, more than offsetting the impact of certain supply headwinds. Overall, we anticipate the supply picture improving during the second half of the year, and that should drive quicker growth, especially in digestive health, while broadly benefiting the whole portfolio. On the bottom line, we delivered a margin of 22.9%, even with substantial spending on innovation, ongoing inflation pressure on our input costs, and some unfavorable currency effects as well. That gain amounts to an 80 basis point increase compared with 2022, and it will further support our continuing operational productivity programs. Going forward, this Q2 result keeps us on track to hit the original 2023 guidance we set. We're confident about reaching the roughly 5% growth guidance we provided at the start of the year, and on the bottom line as well, we think we can sustain profitability of about 23%. Let me now shift gears and go into more detail on innovation within our space.

Heiko Petersen

executive
#27

As I said before, our industry has a crucial purpose. Every day, we're here to help people take better care of their health. Stefan and his team are pushing forward in the fight against serious diseases, while we concentrate on a different side of the health continuum — helping individuals prevent and treat everyday ailments. Science-based self-care, we know, always begins with informed and empowered decision-making, and digital technologies present boundless opportunities to break down these barriers to credible, personalized health information. That's why we set up a specialized precision health unit within our organization to really concentrate on this area. We've also begun partnering with some leading players in digital health. One is called Ada Health, and the other is called Huma, giving consumers more individualized insights into their health. As one example, in a single project, Ada's AI-powered symptom checker helped 200,000 women in the U.K. better understand their intimate health, directly on the website of our large Canesten brand. The activation produced a sales conversion rate for Canesten more than 6x the industry average, and it made our brand website the number two destination for women's intimate health in the U.K., just behind the NHS.

Heiko Petersen

executive
#28

Work like this really highlights how precision health can strengthen our brands, help healthcare systems, and deliver more personalized care to the people we exist to serve. So with that, thank you for listening, and I'll turn things back over to Oliver.

Oliver Maier

executive
#29

Thanks a lot, everyone, for that overview. Ahead of starting the Q&A, I'd like to remind all of you to limit yourselves to roughly two or three questions each, which will let us get through as many participants and questions as we can within the time we have. Just to make sure the audio stays clear, I'll say again: please use a speaker or a landline rather than a headset or a cell phone. With that, Natalie, I believe we're ready to open up the lines for questions.

Operator

operator
#30

Thanks a lot, ladies and gentlemen. We're going to start the question-and-answer portion now. If you'd like to pose a question, you can press star then one on your touchtone phone. Should you want to drop out of the question queue, just press star then two. If speaker equipment is what you're on today, kindly pick up the handset before you make your selections. Anybody with a question can press star then one right now. Our first question comes from Michael Leuchter at UBS. Go ahead, please.

Michael Leuchten

analyst
#31

Thanks a lot. Many thanks, Bill, for those opening comments, and Wolfgang, thank you for laying out the dividend so clearly. I have one question each for Bill and Rodrigo, if I may. Bill, your remarks on strategy and structural issues came through very clearly. I was wondering whether I might draw you out a bit on what you see as the structural issues that need addressing, even if it may be somewhat early in your journey. Then for Rodrigo, it is probably too soon for you to say anything about 2024, but could you tell us when the price cards should be expected? Does that follow the usual timing relative to previous seasons? What is your view of them, and how does shipping into Latin look right now? That business sounds like it is doing quite well. Are you running into any of the destocking problems that some of your competitors have had this year? Thank you.

Bill Anderson

executive
#32

Sure. Thanks, Michael. Yeah, I'd say the question is straightforward. What we're really asking is whether our structure—with the three divisions and the group headquarters arrangement we have—positions us to be the best possible home for each of these businesses when it comes to delivering innovation, serving customers, staying customer-focused, and truly creating value. If you look at a company like ours, we've got fantastic products, but we also have a genuine product integration capability. Crop Science is a good example. We've got seeds, we've got chemicals, biologics, digital farming solutions, and then we have several offerings sitting right at the intersection of those. We need to ensure we're as well positioned as possible to capture that potential. As I travel around and talk with people, I pick up feedback similar to what you'd hear at other big corporations—about processes, about how fast things move, about the tempo. One thing the management board is intensely focused on is this: how do we dramatically speed up everything across Bayer? Other large companies are not the yardstick we measure ourselves against.

Bill Anderson

executive
#33

We’re measuring ourselves against a sole proprietor, a start-up. We have to satisfy ourselves that the structure we choose genuinely helps achieve that aim of speed, innovation, and quality. In essence, that is what we are committing to. I believe this is genuinely thrilling for Bayer’s people, since, once more, we have an excellent mission, yet Bayer, in common with numerous big corporations, earns strong praise for the mission, for the science, and for the inventive concepts, but occasionally something disappears between that point and getting it to the customer quickly. Much of our focus is there.

Rodrigo Santos

executive
#34

Michael, let me turn to the other questions you raised regarding Crop Science. I'll begin with your comment about LatAm. Sure — July sales, for instance, give us a strong signal of how we expect the second half of the year to unfold. We feel confident about the orders we hold for LatAm. Our price cards for LatAm were already put into the market, and as we noted here, we achieved a double-digit price increase in corn and seed, and orders are coming in. On glyphosate as well, we're seeing that as soon as we make the price adjustments we also discussed here today. We're confident on that front. For the northern hemisphere, I'd say it's still too early to tell. We are working on pricing. What I can tell you today is that for next year, we foresee the same approach we've always applied — innovation-based value pricing, more precise pricing that we tailor depending on the technology, the performance, and the hybrids we offer. Probably not at the level we saw in 2022, but we will keep using our innovation-based pricing methodology in the years ahead, not just for 2024, but for 2025 and 2026.

Rodrigo Santos

executive
#35

Regarding that final question you raised, I believe it's a really important one. I talked about how Chinese generic stocks affected sales of our Roundup glyphosate during the first six months of the year. Unlike what you brought up concerning the other competitors, we aren't dealing with a channel inventory problem in our CP portfolio—and even less so in our seeds and trade business, correct? That reflects clear operational management within this organization. Each month we review inventory, and we make adjustments to our sales. The whole organization is truly focused on what we call sell-out—on actual farmer usage—and that is what we're managing. This will benefit not just the second semester of this year but the next season too. Thanks for your questions.

Michael Leuchten

analyst
#36

I appreciate that.

Operator

operator
#37

The next question comes from Richard Foster at JPMorgan. Please go ahead.

Analyst

analyst
#38

Hi, thank you for taking my questions. Three, please. First question, just for Bill. You highlighted in your opening remarks the need to invest in pharma, and I just wanted to understand how you're thinking about the ability to free up capital in Bayer to do this quickly, as you mentioned, speed. You know, long term, probably more options, but in the short term, you know, cost-saving programs, given the location of your costs, how, how are you thinking about the ability to free up cost or capital in that, in that way? Also in terms of maybe longer-term structural changes, you know, when we've seen those being delivered at companies like GSK and Novartis, they've taken many years to deliver. Just your thoughts there, please. Second question, just on crop as well. Just thinking about crop margins going forward, we've got normalized glyphosate, of course, price going up a little bit at the moment, and the rest of the business performing well. How should we think about margins in going forward? Should they be at the same level, or could they even be lower as the SDI provisions come back into the cost mix again? Final quick question, just Kerendia, the Rx, seems to be flattening on the curve.

Analyst

analyst
#39

So is heart failure now the area we're watching, with the readout coming next year, to drive growth toward that EUR 3 billion target? Thanks a lot.

Bill Anderson

executive
#40

Great. Yeah, regarding how we allocate capital — Stefan can add more here — our overall stance is that the portfolio changes made over the past few years... Stefan and Christian Rommel and the team, I think, have done an excellent job of pruning out some of the lower-value programs and made some really good investments in new technologies and some exciting areas. I happened to be at Vividion in San Diego at, I believe, the end of June, when their second IND came through on the very day I was there. That's one example of a truly tremendous platform that is practically an early-stage pharma pipeline in a very small package, since they have so many targets they're pursuing with their really unique technology for going after sort of undruggable things, and they're getting hits, and it's really amazing. I think we don't have a large capital war chest to go and make big acquisitions, but I don't think either of us is particularly inclined to do that, because I think the industry's track record in late-stage acquisitions is really poor, and we prefer to be disciplined and bide our time with a combination of, you know, internal innovation and sourcing earlier innovation from the outside.

Bill Anderson

executive
#41

Take something like Vividion — you know, they might produce several INDs annually over the next few years, and that, that translates into a substantial investment need. These aren't, you know, these aren't large-ticket items. It's, it's phase I, phase II, so I, I think that, that, that's roughly the outlook there. You're right, in, in terms of structural options, one challenge with structural options is the, the time and attention needed to pull them off, so we're, we're weighing all of this as we look at various structural options, and, and we have to factor that in. Again, we're, we're gonna, we're gonna look at everything very thoroughly because we've, we've got an opportunity to, to really get it right, and it makes a big difference. That's our, that's our plan. Let's see, Rodrigo, do you want to take up the crop margins question, and then...

Rodrigo Santos

executive
#42

Absolutely.

Bill Anderson

executive
#43

Stefan, what about Corinda?

Rodrigo Santos

executive
#44

Alright, let me address that point. I'll take the margin question. There are three elements involved here for—naturally, it's too early to discuss the financials for next year, but as I look ahead to the coming years, three components matter greatly. The first is our innovation. Our pipeline, what we're getting ready to launch—and you caught a glimpse of some of it on the charts today—includes the fact that we're now running trials for short stature corn. We're preparing the launch of HT4 along with numerous other expansions in our pipeline, across different areas and different regions too. For us, this is the primary driver of future growth and future margin expansion. There's a second component that's very important, which we are addressing, and we're beginning to see it. Naturally, we saw a significant cost increase over the last two years due to inflation, due to the war in Ukraine, and the impact on the whole supply chain, energy cost—and we're starting to see raw materials and energy prices declining, and that should be reflected in our future cost of goods. This is something we're working on very diligently as well, since it's an important component of our P and L.

Rodrigo Santos

executive
#45

And then, naturally, there's what we hold in terms of operational efficiency, the contingencies we keep, and the way we're adapting how we run things to ensure we stay effective going forward too. Those three pieces are going to keep shaping our margins down the road and, above all, as I mentioned at the start here, they'll fuel our growth ahead. With that said, I'll hand things over to Stefan.

Stefan Oelrich

executive
#46

Thanks, Rodrigo. Hi, Richard. To put it plainly, you're correct that over the past two months the scripts have been leveling off somewhat, and that aligns with the market growth for DKD, meaning diabetic kidney disease, flattening as well. We aren't the sole driver of that expansion, so we also depend on others besides us generating buzz in this category. My hope is that this still offers considerable room to grow, since the disease remains undiagnosed, or underdiagnosed, and undertreated. There ought to still be some fuel in the tank, some gas in the tank, for DKD. You're absolutely right. Naturally, we're also counting on heart failure. At present we have one pivotal trial under way, and we'll be launching a few additional clinical ventures in heart failure, though I'll share more on that once we have it going on clinicaltrials.gov. It's about to start. Perhaps one last point on capital allocation. I think Bill put it very well. Looking at the pharma business today, and I believe the first six months demonstrate this, we're facing considerable margin pressure, stemming from mix, from growth, and from cost increases, inflation here, and from price, of course.

Stefan Oelrich

executive
#47

Our R&D spending has stayed level, and in fact we've nudged it up a bit within this mix. There's a ceiling on how much additional R&D expense we're able to put into the mix, so that, I believe, tells us not only about firing power but also about what we can realistically allocate. Over the coming few quarters, you'll see us doing more early-stage R&D deals, smaller in size, which simply add to the usual preclinical and perhaps very early clinical-stage mix of our portfolio.

Operator

operator
#48

Our next question comes from James Quigley at Morgan Stanley. Please go ahead.

James Quigley

analyst
#49

Thanks a lot. I appreciate the chance to ask. I have three questions, please. One is for Bill and two are for Stefan. Bill, you said you've been out talking with a lot of people. I suppose a key question is this: how open is the Bayer team to this change? It seems there's going to be a fairly significant cultural overhaul, especially given the bureaucratic nature you pointed to earlier. How willing will the team be to change, and how big a challenge do you see that as? On the pharma business, Stefan, you said recruitment for asundexian is ahead of schedule. What has been driving that? How receptive have the sites been to the trial? To what degree could the current pace of recruitment pull forward the potential readout timelines for the trial? One more on Nubeqa growth. You've given us some absolute numbers on NBRx, but where are you now heading in terms of NBRx share? I don't know whether you have that by indication, but it would be very useful. Maybe just NBRx share for Nubeqa versus the class as a whole. Give us a sense of where you are now and where you're headed.

James Quigley

analyst
#50

I appreciate that.

Bill Anderson

executive
#51

Thanks, James. So your question was about how open folks at Bayer are to change. I've got to tell you, I've been genuinely very impressed by the people I've met across all the sites. I believe I've visited roughly 15 sites up to now. There are a few more still to come, but the people are — how should I put it? What stands out to me? First of all, people here are deeply mission-oriented. Those at Bayer take the mission statement very seriously indeed. I can tell you that the people in pharma are genuinely excited about the new molecules and the chance to do great things for patients. Those in Consumer Health feel strongly about the latent opportunity in self-care and about improving access to care for all kinds of people. There is so much unmet need that simply goes unaddressed because of a disconnect between patients, or people with health needs, and awareness of products — and the same holds in Crop Science. You know, you've heard plenty about the offering that Rodrigo described, and about what we can do for farmers, for consumers, and for the planet as well. That runs really deep here, and I don't go anywhere without hearing people talk about it.

Bill Anderson

executive
#52

Second, regarding culture change—incidentally, I've worked 25 years in assorted leadership roles, and I'd say the first 20 of those years went into pushing one culture-change effort or another. My conclusion, in the end, is that you can craft plenty of terrific slogans, yet altering a culture is extremely difficult. What I've come to understand over roughly the last six or seven years is that culture change is actually quite hard to pull off, and it gets somewhat overrated. The reason is that real impact comes from changing the mechanics of how work gets done. Take this example: is it 1% of people deciding what the other 99% of people do? Or is it the 99% of people deciding what they themselves do? Honestly, that isn't a culture change. Some folks will say: "Oh, sure, if you want that changed, you have to change the culture." My experience is that you can tell people as much as you like, "Oh, no, no, you're empowered. You make the decision." It genuinely doesn't work, since they aren't empowered. When the hierarchy sets the budget, and that budget is set once a year, then you can assure people of their empowerment as much as you want, but in essence, they are not.

Bill Anderson

executive
#53

That's, that's not real empowerment. What's genuinely thrilling is when you rewrite the rules and declare, "Hey, guess what? Decisions won't be made that way any longer. We're not, we're not staying on annual cycles. We're moving to 90-day cycles. Everybody goes into teams. Those teams are empowered to decide, and, and the teams figure out the resources among themselves." Once you do that, you release an entirely different level of energy. I have every reason to believe the people of Bayer will adopt that kind of system extremely well, because it isn't some vague culture thing. It's, it's highly practical, and it's completely in line with that mission orientation. It's, it's the place where a, a, a practical solution meets a deep motivation to drive progress for, for patients, for farmers, for consumers. You can tell I'm a bit excited about that, and I, I think regardless of what we decide about, about structure, we have a massive opportunity to unlock the, the, the potential of the people of Bayer, and I know we, we can't wait to get started on that. Stefan, over to you.

Stefan Oelrich

executive
#54

Thanks, Bill. And thanks, James, for raising that question. Regarding asundexian, I’d say there are two parts to this. First, I believe it’s now clear to everyone that we truly have considerable strength in clinical operations on the cardiovascular side. Our strong track record is evident in our capacity to enroll patients and to open new centers. I also think the value proposition of asundexian itself plays a role. Having an anticoagulant that carries a greatly lowered bleeding risk, across the two patient populations we are studying — whether stroke patients or atrial fibrillation patients — really demonstrates, in my view, the substantial unmet need in those two indications. We are delighted that things are moving in the right direction. It is still early days. We still have a bit of a way to go. Let’s not count our chickens before they hatch, but this truly is a step in the right direction. On Nubeqa, when it comes to growth, we are not finished with the non-metastatic setting. We still expect our total share there to increase over the coming couple of years. To achieve that, we need continued strong NBRXs. I think this, again, is heading in the right direction.

Stefan Oelrich

executive
#55

And keep in mind that with ARANOTE, we ought to broaden our spectrum considerably in the metastatic setting, which should drive further growth. Honestly, I'm struck by how quickly we're expanding in the metastatic setting as well. As you know, ARASENS leaves us with a fairly sick population by the end here. With ARANOTE, we should widen this considerably. Bear in mind, you asked about the U.S., but China is now arriving strongly too. It isn't solely a full lift from the U.S.; we're also seeing other regions contribute. Even the Europeans, notoriously difficult, are seeing the added benefit relative to existing therapies of Nubeqa, and we're going to see additional lift from there as well. Thank you.

Michael Leuchten

analyst
#56

Thanks a lot. Appreciate it.

Operator

operator
#57

Our following question comes from Peter Verdult at Citigroup. The line is yours — please proceed.

Peter Verdult

analyst
#58

Thanks. This is Peter Verdult from Citi. I have two questions. Bill, sorry—this is a variation on the theme—I'll ask the first one, then a quick one for Rodrigo. Maybe I'll begin with that. Rodrigo, we've observed a bounce of nearly 60% in glyphosate prices off the June lows. I just wanted to know whether that is reflected in the revised guidance you gave for crop, or whether we can assume you've perhaps been more conservative. I just want to know what has been captured and what hasn't. Then, Bill, again a variation on the theme. Whether rightly or wrongly, there's a narrative in the market that your freedom to operate is constrained by, among other things, you know, the supervisory board, the works council, the balance sheet, sheet structure, and the litigation overhang. On one hand, do investors simply have to be patient and wait for the delivery of farmer and crop innovation? Or are you just not being given enough credit for how actively you are considering, you know, the group structure and, and, and the best structure going forward? I wanted to sort of balance those, you know, those factors and discussion points in the market. Thank you.

Bill Anderson

executive
#59

Great. Rodrigo, would you like to kick things off?

Rodrigo Santos

executive
#60

Yes, I can do that. That one has a straightforward answer. For the rest of the year—the upcoming six months—our forecast essentially relies on the historical price for glyphosate. That's visible on the slide too. It reflects the historical price, prior to any of the increases we saw at the end of 2021 and in 2022. I believe our assumption there is the right one. It doesn't factor in upside from the recent spike you're probably referring to. Over the last two weeks, we observed an increase on the PRC. We'll need to verify that to see whether it holds and remains, and we'll price dynamically the way we do for glyphosate. What our forecast assumes is the historical level we had. With that, Bill?

Bill Anderson

executive
#61

Okay, and thanks, Peter, for your question. Let me try to figure out the simplest way to respond to that. Here we go. What it really boils down to is what I mentioned in my earlier remark. I believe the management board, the supervisory board, the shareholders I've talked with — and honestly the employees too — everyone is firmly convinced that this company's mission is too important not to pursue at 100%. We are looking at every possibility. If we reach the conclusion that the group's structure needs to change so we can achieve our... that is what we will do, because we don't have the luxury of simply asking, "Well, what do we feel like?" We must deliver the greatest value for farmers, for patients, for consumers, and in the end for the people and shareholders of Bayer. That has been my understanding from the very moment I took this job. Now, do different parties have preferences? Certainly, preferences exist. It isn't about preferences. We must act in the company's best interest and in the mission's best interest, and we are exploring every option fully.

Michael Leuchten

analyst
#62

Appreciate it.

Operator

operator
#63

Our next question comes from Sachin Jain at Bank of America. Please go ahead.

Sachin Jain

analyst
#64

Appreciate the opportunity to ask. This is Sachin Jain from Bank of America. Bill, I've got a broad question for you, and it has several parts. During your opening remarks, you mentioned that three factors have been holding the company back: litigation, debt, and corporate bureaucracy. I'm curious whether you could briefly address how you plan to solve each of those. Let me ask specifically about each. First, how do you view the PCB litigation at this point, and what is the current status of the glyphosate cash outflow? Second, regarding the debt — clearly, leverage is significant... what's your route to reducing it? I'm not sure if you or Wolfgang could speak to what the business's underlying cash flow power actually is and when we might be able to see it. Third, on corporate bureaucracy, I'm just trying to get a sense, as you respond to the earlier questions, how much of that stems from the culture at Bayer that you're able to unlock, you know, comparable to what you accomplished at Roche over the last couple of years? And how much do you believe is tied to group structure, which only a breakup could fix? Thank you.

Bill Anderson

executive
#65

Yes, thank you. Thanks, Sachin. Let me take this. To start with litigation, I'm not sure there's much I can add. Wolfgang, I'll let you comment, but my sense is that we know this: we need to be extremely firm when facing our opponents — another one of them, I suppose — who view us as somewhere they can build a profitable business, and we plan to protect the company's interests as fully as possible. I'll check whether Wolfgang wants to add anything. On the debt, we clearly need to strengthen our financial results. The top way we can bring debt down is by outperforming, and that remains a key priority for the management board, for our talks with employee representatives, and for the people at Bayer. As for how to accomplish that — take corporate bureaucracy, for instance — how much of it stems simply from being a big company, and how much is specific to the corporate structure? I think that's part of what we're working through. That's the reason we're spending time assessing these matters right now.

Bill Anderson

executive
#66

I'm, I'm sure there is enormous potential — no matter what the structure ends up being, there's enormous potential to unlock the power of people. Because in, in every, you know, multinational company that's oriented around hierarchy, there, there is a better way of doing things, and the smartest companies on earth are working that out. Most companies haven't done so yet, but, but people are working it out, and I believe there's a tremendous opportunity to do that at Bayer, again, regardless of what decisions we make about, about structure. Wolfgang, any further comments on litigation?

Wolfgang Nickl

executive
#67

Sure, happy to. Hey, Sachin, how are you? On litigation, there's honestly not much to report — nothing material. Glyphosate, as you put it well, we're sharply focused on carrying out our five-point plan. Yes, roughly 115,000 of the cases are done. Around 160 are locked. As you mentioned, having an accrual doesn't mean we're prepared to write checks. In fact, the team is quite proud of having won the most recent seven cases. As you can imagine, the other side didn't lead with their weakest cases, so those wins came in tough jurisdictions, and we beat tough opponents. We fully intend to keep that up. We'll carry out the five-point plan, such as swapping the active ingredient for our U.S. lawn and garden market. The plan we've put in place is being executed, and executed very well. On PCB, there's little to add. Monsanto and its predecessor company stopped selling this product almost 50 years ago. We'll defend ourselves. Obviously, we have a couple of items ahead, such as the appeals and post-trial motions in the Sky Valley cases. One area we're putting a lot of emphasis on is enforcing the indemnifications we had against our former clients, which we believe are pretty strong.

Wolfgang Nickl

executive
#68

We're pursuing several of them in the electrical space that account for a large majority of the shipments involved. Keep watching for updates on that. On debt, I think the picture is fairly clear. Yeah, cash flow performance made this a difficult year. We wish we had done better, but I have zero doubt this isn't a trend. In fact, some of the factors that pulled cash flow down this year could just as well become a tailwind next year. Our goal of reaching an A rating hasn't changed. As Bill also mentioned, we are laser focused on embedding cash flow management deeper into the DNA. We're making solid progress there. I'd like to share one other data point, and this is almost like a lucky punch, but it matters when you build your models. When you examine leverage, you look at net financial debt, but you also look at the net pension liability. In the higher interest rate environment, our net pension liability has actually decreased by EUR 2 billion over the last four quarters. From a pure leverage standpoint, that works in our favor. That's not an excuse.

Wolfgang Nickl

executive
#69

That's just extra context. Our attention is squarely on free cash flow, and we keep pursuing our goal of being a A-rated company.

Michael Leuchten

analyst
#70

Thanks.

Wolfgang Nickl

executive
#71

Happy to have you with us.

Operator

operator
#72

We’ll take the next question from Vincent Andrews at Morgan Stanley. Vincent, you have the floor.

Vincent Andrews

analyst
#73

Thanks for taking my question — just the one from me. Rodrigo, could you share a bit about what you're expecting for Intacta2 penetration this season? How much of the pickup will there be, and how much of that is driving the 10% price mix you mentioned, versus what you're anticipating on the corn side of the book?

Rodrigo Santos

executive
#74

Thanks, Vincent. Yes, we priced Intacta 2 this year with a 10% — with a double-digit price increase in Latin. We're seeing the penetration we projected for the new trade, correct? Also, taking your question as a chance to note that we're already working on Intacta 3 and Intacta 4, the next generations for Brazil too. We're seeing the penetration we mentioned, 5, 6 million acres of Intacta 2 in the ground. Its performance — I've been getting the trials and the harvest from the farmers — has been very, very positive. A lot of excitement around our soybean business in Brazil specifically. Thank you.

Operator

operator
#75

Our next question comes from Emily Field at Barclays. Please go ahead with your question.

Emily Field

analyst
#76

Hello, and thank you for taking my question. I actually have two. First, specifically regarding EYLEA, I'd really like to hear your perspective on how you're currently viewing any competition from Vabysmo in those markets where it has launched. And then, perhaps over the longer term, Bill, it would be great to hear your thinking on just what the opportunity looks like for the high-dose EYLEA. Second, another fairly broad question. One thing we hear a lot about is essentially the ESG overhang that the company is facing, and there has been some — you know, a lot of progress has been made, and part of that overhang sits outside the company's control. It would be great, Bill, to hear your thoughts on what can proactively be done to keep that improvement going, specifically on ESG. Thank you.

Bill Anderson

executive
#77

Stefan, would you like to kick things off with EYLEA?

Stefan Oelrich

executive
#78

Yes. Hello, and thanks for asking. We feel pretty good when you examine the volume growth we're actually delivering for EYLEA worldwide—it's honestly stronger than what you folks observe on total sales. That reflects the resilience we've got, even while up against competition. In this instance, Bill is well versed in the competitive pressure coming from faricimab. What we observe is that they are picking off the easy wins—meaning the clear-cut patients who are switchable. We aren't seeing them push much beyond that within our territories. Over the medium to longer term—and before I pass things to Bill, since I believe you directed that question at him—I would expect that given the outstanding data from our high-dose aflibercept 8 milligram program, which we plan to launch during the first half of next year, matters will only improve. We remain very confident in our capacity to stay the gold standard in this market. Bill, over to you.

Bill Anderson

executive
#79

Yeah. On ESG progress, I'm genuinely proud of what Bayer has achieved — honestly, one of the biggest reasons and one of the biggest motivations behind my decision to join this company was the truly remarkable part Bayer plays in, yeah, sustainability especially, in climate change and regenerative agriculture. I think if you examine it carefully, we've got major efforts — by the way, I'd suggest, you know, heading to our website if you'd like to see some of what we're doing and some of the programs we've got, since we're very widely acknowledged as a pioneer in sustainable agriculture. If you look at the acreage of no-till farming globally and how much of that is driven by our crop protection and, and seed technology. When it comes to our, our ESG ratings from the various rating groups, we, we're almost always in the top half, if not the top quartile, versus our, our peer companies, whether that's in Pharmaceuticals or in Crop Science. Yeah, I, I think we're, we're not content with that, and we wanna, we wanna keep improving year after year. I think, probably the largest challenge we face is certain ratings that go along with, like, for instance, GMO foods and conclude, oh, GMO is bad, and so, you know, we wind up with a bad rating, and we're having to do education about that.

Bill Anderson

executive
#80

In my view, we're making solid headway. The proposed law in Europe that treats CRISPR-edited genetics as something potentially licensable down the road — I think that's a genuinely significant favorable development. And I think it matters as an expanding number of people come to understand that modifying plants genetically ranks among our biggest tools for combating climate change, for combating hunger in the future, and for developing crops better able to withstand drought. The key point is, I'd say the strides made up to now are considerable, and there's plenty more we can accomplish. Appreciate the question.

Stefan Oelrich

executive
#81

Thanks, everyone. I need to keep an eye on the clock here. Natalie, I believe we can fit roughly two more rounds of questions, if that works.

Operator

operator
#82

Our next question comes from Florent Cespedes at Société Générale. Please go ahead.

Florent Cespedes

analyst
#83

Good afternoon, and thanks so much for taking my questions. I have two quick ones. First, for Heiko: how do you view the pricing environment moving forward? Do you think price increases like these can be sustained? Where might there be some businesses where you could raise prices, while, you know, others prove more difficult? More color and more granularity on this would be great. My second question is for Stefan. On China, you mentioned that the post-pandemic recovery has been softer than expected. Some granularity and more details would be great. Is it because of lower demand? Are you seeing more competition? Is there more pricing pressure? Any color would be great. Thank you.

Bill Anderson

executive
#84

Thanks. Heiko, over to you.

Heiko Petersen

executive
#85

Alright. Let's tackle pricing first. I'd say, broadly across the entire consumer sector, we've witnessed a substantial amount of price increases over the last few years. Clearly, much of that was pushed by elevated input costs. And of course, we're making a big effort to get those costs down, because we're beginning to notice — as our volume figures show — that consumers' capacity to absorb it is being affected. Our retail partners, too, are telling us they want us to be more responsive and lower prices. We're putting real effort into that. It comes down to this: we did accept certain price hikes from suppliers over the past couple of years, since there was a genuine justification — energy prices, for instance, were so elevated that they fed through into packaging and so forth. Now that those costs are declining, it's their turn to flip the coin and reduce prices as well. That means being a little stricter with our suppliers once more. Secondly, we're clearly also doing everything we can to offset this by finding productivity improvements at our production sites.

Heiko Petersen

executive
#86

To give a short answer, we also believe that taking 10% pricing every year isn't sustainable. Let's be honest: inflation will likely run somewhat higher than the levels we grew accustomed to over the past 10 years. It may not reach 10%, but continued pricing will probably exceed what we saw during the past 10 years, since inflation is simply more here to stay. The one possible exception where you can genuinely push a bit more pricing is, clearly, when you bring innovation, when you offer truly exceptional products. That's partly why, as Bill mentioned, in the Bayer Consumer Health business we work hard to add more science to our products, because you could argue that not every product in the consumer space has very solid science behind it. We see that as one of the genuine advantages of being part of Bayer. There's more expertise in how to pursue science-based innovation and also in discussing it with regulators so we can land the right claim. Genuine innovation is what will deliver it, including those switches, by the way.

Heiko Petersen

executive
#87

Those are the things we're concentrating on.

Florent Cespedes

analyst
#88

Thanks.

Stefan Oelrich

executive
#89

Modular flow. So yes, regarding China, I think it arrives in, in, in, in two shades of gray, so to speak. One is, naturally, the VBP-affected products such as Adalat and Xarelto, where a negative impact was anticipated. There are a few of our, shall we say, other established products that aren't currently subject to VBP, like, for instance, our contraception business. What we're observing right now in China, where we'd enjoyed fairly consistent growth rates of 20%, 30% annually coming out of this pandemic situation, is that this year we were negative on contraception, both long-acting and shorter- short-acting, which is something that, so to speak, resembles somewhat what we witnessed post-pandemic in certain other geographies worldwide, though we didn't necessarily anticipate that from China. The strength in China is evident in our innovative products. I mentioned Kerendia, I mentioned Nubeqa, where they come out of the gate extremely strong, in fact strongest in terms of share, in any w- any geography that we have worldwide. Additionally, EYLEA keeps performing very, very well in China. We're witnessing a clear portfolio shift here from the older products toward, toward innovation.

Florent Cespedes

analyst
#90

Thanks a lot, Stefan.

Operator

operator
#91

Our next question comes from Steve at Bank of America. Go ahead, Steve — your line is open, so you may need to unmute your phone.

Steve Byrne

analyst
#92

Yeah, apologies for that, and thanks for making room for me. I've got a question for Rodrigo. What would you say is the main thing that limits your ability to know where crop chemical levels stand in the channel? It looks like an industry-wide problem, and it was a big one with glyphosate. Is glyphosate perhaps harder for knowing stock levels because it sits in bulk storage tanks? Your fungicide and insecticide volumes appear to see less destocking. My question is whether there's a way to improve on that.

Rodrigo Santos

executive
#93

Okay, so let me address that question. When it comes to the inventories in the channel that we have, we track that on a monthly basis. We get that data from all of our products, and it's a very important tool that we use to adjust our sales and to do what I mentioned about what we call internally sellout — really focusing on farmers' usage, the sales that we have in our organization. That one, we have it under control, and that's why I said we don't have issues with inventory in the channel today, globally. We have a very healthy level of our products in any region where we operate. I think that's the one piece. Competitors' inventory is harder to access. That's the information that is, of course, more sensitive. We don't have that information, and we cannot access that information. We monitor a little bit of some public information that we have in terms of imports and exports, but I just want to reconfirm what we have. When you see the sales that we have in the first six months of the year or now the orders that we are seeing in July and so on, we have a very healthy inventory of our products, all our SBEs, on a global basis.

Rodrigo Santos

executive
#94

That's a really key part of how we run things at Bayer today. Thank you.

Stefan Oelrich

executive
#95

All right. Thanks to everyone for your questions, and of course to everybody here on the team, really, for all the answers. I realize quite a few more people are actually still in the queue. We do have some other commitments, so please reach out to investor relations, to the team. We're more than happy to follow up offline on any questions you may have. With that, I want to thank everyone for your time and attention today. We really appreciate it, and that brings the call to a close for today, and talk soon. Thank you very much. Appreciate it. Bye-bye.

Operator

operator
#96

Ladies and gentlemen, that brings the conference to a close. You’re welcome to disconnect now. Thank you so much for being with us. Have a pleasant day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.